在第二阶段癌症试验协议中支持证据:内容分析
Selin Bicer1, Angela Nelson1, Katerina Carayannis1
1Department of Equity, Ethics and Policy, Studies of Translation, Ethics and Medicine, McGill University, Montreal, QC, Canada.
Journal of the National Cancer Institute
|November 12, 2024
概括
在2期癌症试验中,支持证据往往不足以进行批判性评估. 协议中经常缺少关键数据,特别是临床前研究,这阻碍了对候选药物的评估.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 翻译科学 翻译科学
背景情况:
- 第二阶段试验对于将癌症候选药物推向疗效试验或加速批准至关重要.
- 在第二阶段试验中的高消耗率表明支持证据基础中的潜在缺陷.
- 评估证据的稳定性对于优化临床试验设计和资源分配至关重要.
研究的目的:
- 开发一种类型学和评估框架,用于支持癌症第二阶段试验中的证据.
- 分析2期癌症单一治疗试验协议中提出的支持证据的内容和强度.
- 识别阻碍批判性评估的证据陈述中的差距.
主要方法:
- 为第二阶段癌症试验创建了支持证据的类型.
- 设计了一个方案来评估支持证据的强度.
- 内容分析对50个随机采样的2期癌症单疗法试验协议 (2014年1月至2019年1月) 从clinicaltrials.gov.gov进行了内容分析.
主要成果:
- 大多数支持性证据来自不同癌症的试验 (56%) 或临床前研究 (96%),而不是目标药物指示 (46%).
- 翻译相关性很少被解释 (2%);通过共享的分子/病理生理过程暗示可翻译性.
- 评估大小,精度和偏差的信息通常可用于临床试验,但缺乏临床前研究.
结论:
- 强有力的支持性证据对于证明临床试验承诺的合理性至关重要.
- 第二阶段单一治疗癌症试验的协议经常缺乏关键证据评估所需的元素.
- 提供支持证据的结构化方法是必要的,以改善试验的合理性和设计.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.5K
相关概念视频
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
Comparing the Survival Analysis of Two or More Groups
154
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
154
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
